First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

000mg (5.6ml)/vial [Efgartigimod Alfa Injection (Subcutaneous Injection)] for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is approved ...

In addition, we're making excellent progress across our other late-stage trials. As announced this morning, the FDA cleared ...

Intellia Therapeutics Inc (NTLA) showcases strong financials and significant progress in its CRISPR-based pipeline, despite ...

Received IND clearance from the U.S. FDA to initiate MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran (nex-z) in patients with hereditary ...

Neuropathic pain affects more than 20 million people in the U.S., and at least a quarter of these cases are puzzling for ...

Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’ Vyvgart is already making headway in the rare disease space, just one of the long-term growt | ...

The NHS Business Services Authority (NHSBSA) has published the latest Innovation Scorecard as an Official Statistic, having taken over this responsibility from NHS England in April 2024, who ...

ROCKVILLE, Md. and SEOUL, South Korea, Nov. 1, 2024 /PRNewswire/ -- HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global ...

The treatment for ATTR in certain adults with polyneuropathy had just been recommended for approval across the European Union and had gained regulatory approval in the United States at the end of 2023 ...